The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Everolimus Versus Placebo in Head and Neck Cancer
Official Title: Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
Study ID: NCT01111058
Brief Summary: Primary: Two-year progression-free (tumor does not grow or spread) survival in subjects treated with everolimus versus placebo after definitive local therapy.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Miami, Miami, Florida, United States
Northwestern University, Chicago, Illinois, United States
University of Illinois-Chicago, Chicago, Illinois, United States
The University of Chicago Medical Center, Chicago, Illinois, United States
Ingalls Cancer Research Center, Harvey, Illinois, United States
University of Kansas, Kansas City, Kansas, United States
Louisianna State University, Shreveport, Louisiana, United States
Tufts Medical Center, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
University of Mississippi, Jackson, Mississippi, United States
Washington University, Saint Louis, Missouri, United States
University of North Carolina, Chapel Hill, North Carolina, United States
Ohio State University, Columbus, Ohio, United States
Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
Vanderbilt University, Nashville, Tennessee, United States
The University of Texas Medical Branch at Galveston, Galveston, Texas, United States
Name: Tanguy Seiwert, M.D.
Affiliation: The University of Chicago Medical Center
Role: PRINCIPAL_INVESTIGATOR